Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
ARTIS Ventures is a venture capital firm founded in 2001 and headquartered in San Francisco, California. The firm focuses on supporting visionary founders who are innovating in critical technologies that enhance human health and resilience. ARTIS coined the term 'TechBio' to describe the convergence of technology and biology, emphasizing their commitment to investing in essential systems that impact global health, infrastructure, and security.
As of 2023, ARTIS Ventures manages a fund size of $200 million, specifically through their TechBio II fund, which closed in December 2023. This fund represents the firm’s fourth fund and is dedicated to companies utilizing data, software, artificial intelligence, machine learning, and deep learning to transform human health. The firm has a portfolio of seven companies, showcasing a strong commitment to the TechBio sector.
ARTIS Ventures has established itself as a leader in the TechBio space, with a mission to back founders who apply frontier technologies to improve the human condition. The firm operates from its San Francisco office and has built a reputation for rigorous due diligence and support for its portfolio companies.
ARTIS Ventures invests in startups at the intersection of technology and biology, particularly in sectors such as artificial intelligence, healthcare, biotech, fintech, and consumer products. Their investment strategy encompasses seed, Series A, Series B, and growth equity stages, allowing them to engage with companies at various points in their development. The firm typically writes checks ranging from $2 million to $15 million, with reserves for follow-on investments.
The firm emphasizes the importance of scalable and accessible health systems, infrastructure, and security frameworks that protect vital systems for human life. ARTIS Ventures seeks to partner with founders who are innovating in critical technologies that enhance human health and resilience. Their investment thesis focuses on supporting companies that leverage technology to transform health outcomes and societal resilience.
ARTIS Ventures has a notable portfolio that includes a mix of historical and current investments. Key companies in their portfolio include:
This diverse portfolio reflects ARTIS Ventures' commitment to investing in transformative technologies that address critical health challenges.
Stuart Peterson: Managing Partner. Stuart has extensive experience in venture capital and has been instrumental in leading investments in transformative technologies. He has a strong background in the TechBio sector and has been with ARTIS Ventures since its inception.
Austin Walne: Senior Partner. Austin brings a wealth of knowledge in healthcare investments and has played a key role in identifying and supporting innovative startups in the sector.
Ruchita Sinha: Senior Partner. Ruchita has a background in both venture capital and healthcare, focusing on investments that leverage technology to improve health outcomes.
Vasudev Bailey: Managing Partner. Vasudev has a strong track record in venture capital and is focused on supporting companies that are at the forefront of technological innovation in health.
Henry Klingenstein: Partner. Henry specializes in healthcare technologies and has a deep understanding of the challenges and opportunities within the sector.
To pitch ARTIS Ventures, founders should submit their proposals through the firm’s website at av.co. The pitch deck should include a clear overview of the technology, market opportunity, and team qualifications. Founders are encouraged to highlight any unique aspects of their approach and how it aligns with ARTIS's focus on TechBio.
ARTIS Ventures prefers warm introductions but will consider direct submissions through their website. Response times can vary, but founders should expect to hear back within a few weeks if their proposal aligns with the firm’s investment strategy.
ARTIS Ventures runs the TechBio Fellows Program, which is a remote, part-time opportunity for advanced graduate students and practicing MDs to gain experience in early-stage venture capital. Participants work closely with the investment team on evaluating startups and technologies, providing them with hands-on experience in the venture capital process.
In December 2023, ARTIS Ventures closed its fourth fund, TechBio II, with a total size of $200 million. This fund is dedicated to investing in companies that utilize data, software, AI, and machine learning to transform human health.
In January 2024, ARTIS Ventures announced the new class of its TechBio Fellows Program, which embeds MDs and PhDs within the investment team to enhance due diligence and support for portfolio companies.
What are ARTIS Ventures' investment criteria?
ARTIS Ventures focuses on startups that leverage technology to enhance human health and resilience. They invest in sectors such as AI, healthcare, biotech, fintech, and consumer products, targeting companies at seed, Series A, Series B, and growth equity stages.
How can I pitch to ARTIS Ventures?
Founders can pitch to ARTIS Ventures through their website at av.co. It is recommended to include a clear description of the technology, market opportunity, and team in the pitch deck.
What makes ARTIS Ventures different from other VC firms?
ARTIS Ventures is distinguished by its focus on the TechBio sector, a term they coined to describe the intersection of technology and biology. They provide in-house scientific expertise through their TechBio Fellows Program, embedding MDs and PhDs within their investment team.
What is the typical check size for investments?
ARTIS Ventures typically writes checks ranging from $2 million to $15 million, depending on the stage of the company and the specific investment opportunity.
What is the geographic focus of ARTIS Ventures?
The firm primarily invests in startups based in North America, aligning with their mission to enhance global health and resilience.
What kind of support do portfolio companies receive?
ARTIS Ventures provides significant value to its portfolio companies through rigorous due diligence, ongoing assistance, and access to their network of experts in the TechBio field.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.